Search Results for "GnRH agonists"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for GnRH agonists. Results 1 to 4 of 4 total matches.
Leuprolide Acetate (Fensolvi) for Central Precocious Puberty (online only)
The Medical Letter on Drugs and Therapeutics • Sep 23, 2021 (Issue 1634)
subcutaneous formulation
of the gonadotropin-releasing hormone (GnRH)
agonist leuprolide acetate ...
Fensolvi (Tolmar), a long-acting subcutaneous formulation
of the gonadotropin-releasing hormone (GnRH)
agonist leuprolide acetate, has been approved by the
FDA for treatment of central precocious puberty (CPP)
in children ≥2 years old. It is the first formulation of
the drug to be approved for SC administration once
every 6 months. IM formulations of leuprolide acetate,
which are given once monthly or every 3 months, and
the GnRH agonists histrelin acetate (Supprelin LA) and
triptorelin (Triptodur) have been available for years for
treatment of CPP.
Relugolix (Orgovyx) for Advanced Prostate Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Jul 24, 2023 (Issue 1681)
) was more effective than the
GnRH agonist leuprolide in achieving and maintaining medical
castration ...
The oral gonadotropin-releasing hormone (GnRH)
receptor antagonist relugolix (Orgovyx – Myovant
Sciences/Pfizer) has been approved by the FDA for
treatment of advanced prostate cancer in adults. It
is the first oral GnRH receptor antagonist to become
available in the US; degarelix (Firmagon), an injectable
GnRH receptor antagonist, has been available since
2008 for the same indication.
Med Lett Drugs Ther. 2023 Jul 24;65(1681):e121-2 doi:10.58347/tml.2023.1681e | Show Introduction Hide Introduction
Myfembree for Fibroid-Associated Heavy Menstrual Bleeding
The Medical Letter on Drugs and Therapeutics • Aug 09, 2021 (Issue 1630)
(NSAIDs) are also used, but they
are less effective.3,4 Injectable formulations of GnRH
agonists ...
Myfembree (Myovant/Pfizer), an oral fixed-dose
combination of the gonadotropin-releasing hormone
(GnRH) receptor antagonist relugolix, the estrogen
estradiol, and the progestin norethindrone acetate,
has been approved by the FDA for management of
heavy menstrual bleeding associated with uterine
leiomyomas (fibroids) in premenopausal women. It is
the second product to be approved in the US for this
indication; Oriahnn, which contains the GnRH receptor
antagonist elagolix in combination with estradiol and
norethindrone acetate, was approved earlier. Relugolix
was approved for...
Oriahnn for Fibroid-Associated Heavy Menstrual Bleeding
The Medical Letter on Drugs and Therapeutics • Apr 05, 2021 (Issue 1621)
menstrual blood loss.3,4 Injectable
formulations of GnRH agonists may be effective,
but they should ...
Oriahnn (Abbvie), a fixed-dose combination of the
gonadotropin-releasing hormone (GnRH) receptor
antagonist elagolix, the estrogen estradiol, and the
progestin norethindrone acetate copackaged with
elagolix alone, has been approved by the FDA for oral
treatment of heavy menstrual bleeding associated
with uterine leiomyomas (fibroids) in premenopausal
women. It is the first product to be approved in the
US for this indication. Elagolix (Orilissa) has been
available since 2018 for treatment of moderate to
severe pain associated with endometriosis. The
GnRH receptor antagonist...